THERAPEUTIC HPPH DOSAGE FOR PDT

1 . A method for treating cancer and other hyperproliferative tissues in humans that can be exposed to light comprising injection of HPPH at the equivalent to a dose of 0.05 to 0.11 mg/kg of body weight 24 hours post injection and exposing the tumor or other hyperproliferative tissue to 665±10 nm of light at 50 to 200 Joules/cm 2 .

2 . The method of claim 1 where the light is 75 to 150 Joules/cm 2

3 . The method of claim 1 where the tissue is basal cell carcinoma.

4 . The method of claim 1 where the tissue is advanced lung cancer tissue.

5 . The method of claim 1 where the tissue is early stage lung cancer tissue.

6 . The method of claim 1 where the tissue is high grade dysplasia carcinoma in Barrett's Esophagus.

7 . The method of claim 1 where the tissue is advanced obstructing esopageal cancer.

8 . The method of claim 1 where the tissue is head and neck cancer tissue.

9 . HPPH for use in treating cancer and other hyperproliferative tissues in humans that can be exposed to light comprising injection of HPPH at the equivalent to a dose of 0.05 to 0.11 mg/kg of body weight 24 hours post injection and exposing the tumor or other hyperproliferative tissue to 665±10 nm of light at 100 to 200 joules/cm 2 .

10 . HPPH as claimed in claim 9 where the light is 75 to 150 Joules/cm 2

11 . The method of claim 1 where the HPPH is injected in a composition comprising 0.5 to 1.5 mg/kg HPPH, 0.05 to 0.15 weight percent surfactant having an HLB of 14 to 16, 1 to 3 weight percent ethanol and 3 to 8 weight percent monosaccharide with the balance being water.

12 . The method of claim 11 where the monosaccharide is glucose and the surfactant is polysorbate 80.

13 . The method of claim 11 where the surfactant is a sucrose ester.